Login to Your Account



Acadia Climbs 134% on $395M Pimavanserin Deal with Biovail

By Trista Morrison


Tuesday, May 5, 2009
Acadia Pharmaceuticals Inc. surprised investors Monday morning by unveiling a potential $395 million partnership on lead drug pimavanserin with Biovail Corp. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription